Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection

Saito, Masaaki; Kano, Mariko; Itagaki, Kanako; Ise, Shigeyuki; Imaizumi, K; Sekiryu, Tetsuju

doi:10.1007/s10384-015-0411-3

Cited by 19 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If their judgments differed, they reexamined the images together to reach a consensus. The diagnosis of PCV was mainly based on the angiographic findings at the time point of aflibercept switch, according to the previous reports;28,33,38,39 a PCV diagnosis was made if at least one subretinal focal hyperfluorescence was observed on ICGA 38. The greatest linear dimension (GLD) at the time point of aflibercept switch was measured based on FA.…”

Section: Methodsmentioning

confidence: 99%

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

Azuma¹,

Asaoka²,

Matsuda³

et al. 2018

OPTH

View full text Add to dashboard Cite

BackgroundThe purpose of the study was to evaluate the 2-year outcome and predictive factors of treat-and-extend aflibercept in patients with eyes affected by typical neovascular age-related macula degenelation (t-AMD) or polypoidal choroidal vasculopathy (PCV), who were switched from ranibizumab.Patients and methodsThe patients underwent three monthly aflibercept injections and subsequent administration following the treat-and-extend protocol. Sixty-two eyes of 62 patients were reviewed retrospectively. R statistical software was used for statistical analysis.ResultsTwenty-two eyes were t-AMD and the remaining 40 eyes were PCV. There was no significant difference in the logarithm of the minimal angle of resolution visual acuity (VA) between baseline and 2 years after switching to aflibercept (0.40 vs 0.40; P=0.99). Multivariate analyses suggested that the following factors were significantly correlated with better VA at 2 years after switching to aflibercept: patients with PCV, the absence of intraretinal fluid at baseline, and better VA at baseline.ConclusionIn conclusion, VA was maintained and there was an anatomical improvement at 2 years in patients with t-AMD and PCV who were switched from ranibizumab to treat-and-extend aflibercept. PCV patients showed more favorable visual outcomes and less injections at 2 years compared to t-AMD patients. Intraretinal fluid and VA at baseline were predictors of VA at 2 years.

show abstract

Section: Methodsmentioning

confidence: 99%

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

Azuma¹,

Asaoka²,

Matsuda³

et al. 2018

OPTH

View full text Add to dashboard Cite

show abstract

“…A significant reduction in subfoveal choroidal thickness is noted after anti-VEGF therapy in AMD and PCV [51, 52]. As stated earlier choroidal thickness measurements below drusen of <135 µm [26], is indicative of evolving geographical atrophy.…”

Section: Biomarkers In Age Related Macular Degenerationmentioning

confidence: 96%

The potential of spectral domain optical coherence tomography imaging based retinal biomarkers

et al. 2017

View full text Add to dashboard Cite

BackgroundBiomarker”, a merged word of “biological marker”, refers to a broad subcategory of medical signs that objectively indicate the state of health, and well-being of an individual. Biomarkers hold great promise for personalized medicine as information gained from diagnostic or progression markers can be used to tailor treatment to the individual for highly effective intervention in the disease process. Optical coherence tomography (OCT) has proved useful in identifying various biomarkers in ocular and systemic diseases.Main bodySpectral domain optical coherence tomography imaging-based biomarkers provide a valuable tool for detecting the earlier stages of the disease, tracking progression, and monitoring treatment response. The aim of this review article is to analyze various OCT based imaging biomarkers and their potential to be considered as surrogate endpoints for diabetic retinopathy, age related macular degeneration, retinitis pigmentosa and vitreomacular interface disorder. These OCT based surrogate markers have been classified as retinal structural alterations (macular central subfield thickness and cube average thickness); retinal ultrastructural alterations (disruption of external limiting membrane and ellipsoid zone, thinning of retinal nerve fiber layer and ganglion cell layer); intraretinal microangiopathic changes; choroidal surrogate endpoints; and vitreoretinal interface endpoints.ConclusionOCT technology is changing very quickly and throughout this review there are some of the multiple possibilities that OCT based imaging biomarkers will be more useful in the near future for diagnosis, prognosticating disease progression and as endpoint in clinical trials.

show abstract

“…used OCT to monitor response to intravitreal aflibercept injections in PCV patients who were refractory to ranibizumab, and showed significant decrease in subfoveal choroidal thickness and significant improvement in visual acuity. (63) Kim et al . similarly used mean choroidal thicknesses measured by OCT as a treatment outcome after initiation of either intravitreal ranibizumab and aflibercept in three disease groups of NV-AMD, PCV and retinal angiomatous proliferation (RAP) and showed significant differences in amount of decrease in the two treatment groups as well as difference between disease groups.…”

Section: Imaging Of Pcvmentioning

confidence: 99%

“…(82) Ranibizumab, bevacizumab, aflibercept, ziv-aflibercept, and conbercept have all been used as therapeutic anti-VEGF agents for PCV and have been shown to reduce exudation and stabilize or improve vision, but have variable effects on polypoidal lesions and choroidal vascular abnormalities. (55,63,85,102–125)…”

Section: Management Of Pcvmentioning

confidence: 99%

“…(113,115,117,121) Additionally, retrospective studies of ranibizumab “non-responders” who were switched to aflibercept treatment demonstrated reduced exudation, reduced choroidal thickness, and stable or improved vision. (63,114) Eyes that were switched from ranibizumab to aflibercept were also noted to have further resolution of PEDs and polyp closure. (117) The differences in outcomes can be due to active transport of aflibercept to the sub-RPE space by RPE cells, compared to gradient diffusion between RPE cells for ranibizumab.…”

Section: Management Of Pcvmentioning

confidence: 99%

See 1 more Smart Citation

Polypoidal Choroidal Vasculopathy

Kim

Nirwan

Kuriyan

2017

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Purpose of Review The goal of this paper is to review the recent literature of polypoidal choroidal vasculopathy (PCV) and provide an update on the epidemiology, pathophysiology, clinical findings, and management. Recent Findings Although indocyanine-green angiography (ICGA) is still the gold standard for diagnosis of PCV, the use of en face optical coherence tomography (OCT) and OCT angiography are useful tools in the diagnosis of PCV. Studies demonstrate superior treatment outcomes with combination photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) therapy. Summary PCV is a disease most commonly in Asians and African-Americans and presents with an orange-red nodule in the macula or the peripapillary region. While ICGA remains the most accurate method to diagnose PCV, newer non-invasive imaging modalities (eg. OCT-A and en face OCT) can be used to identify PCV lesions. The combination of PDT and anti-VEGF therapy is superior to either monotherapy. Future studies of OCT modalities and other anti-VEGF agents will be important in guiding PCV diagnosis and management, respectively.

show abstract

Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection

Cited by 19 publications

References 35 publications

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

The potential of spectral domain optical coherence tomography imaging based retinal biomarkers

Polypoidal Choroidal Vasculopathy

Contact Info

Product

Resources

About